Durability of Early Combination Therapy vs Conventional Therapy in New Onset T2DM
早期联合治疗与传统治疗在新发 T2DM 中的持久性
基本信息
- 批准号:9324995
- 负责人:
- 金额:$ 48.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-01 至 2018-08-31
- 项目状态:已结题
- 来源:
- 关键词:AmericanApplications GrantsBeta CellBlood PressureBody WeightBody Weight decreasedBudgetsCell physiologyCombined Modality TherapyDefectDevelopmentDiabetes MellitusDiagnosisEuropeEventFactor VFailureFunctional disorderFundingGlycosylated hemoglobin AGoalsGrantHepatocyteHyperglycemiaHypoglycemiaHypoglycemic AgentsImpairmentIndividualInsulinInsulin ResistanceMetabolicMetforminMicrovascular DysfunctionMuscle CellsNewly DiagnosedNon-Insulin-Dependent Diabetes MellitusOralPathogenicityPharmaceutical PreparationsPharmacologyPioglitazoneProgress ReportsRegimenRiskRisk FactorsSafetySulfonylurea CompoundsTherapeutic UsesTimeUnited States National Institutes of HealthWeight Gainarmbasal insulinblood glucose regulationcardiovascular risk factorconventional therapydiabeticexenatideexperiencefollow-upglycemic controlimprovedinsulin sensitivitypublic health relevance
项目摘要
DESCRIPTION (provided by applicant): Hyperglycemia is the major risk factor for the development of diabetic microvascular complications. The ADA recommends lowering the A1c in T2DM individuals to levels (i.e. HbA1c <6.0-6.5%) "as close to normal as possible while avoiding hypoglycemia". The optimal pharmacologic therapy which achieves this goal never has been determined. We have demonstrated that starting newly diagnosed T2DM individuals on a combination of agents (metformin, pioglitazone, exenatide) which correct known pathophysiologic defects in T2DM (Triple Therapy) produces a greater decrease in HbA1c compared to stepwise addition of metformin, sulfonylurea and insulin (Conventional Therapy) and that the decrease in HbA1c was maintained for 36 months of follow-up. Subjects receiving Conventional Therapy experienced significant weight gain (3.7 kg) and a higher rate (7.4-fold increase) of hypoglycemic events compared to subjects receiving Triple Therapy who lost 3.1 kg of body weight. Moreover, Triple Therapy produced profound increases in insulin sensitivity and beta cell function compared to Conventional Therapy. In this grant, we propose to continue to follow-all currently active subjects for an additional 36 months to obtain information about the long term efficacy, durability, safety, and mechanism of action of Triple Therapy compared to Conventional Therapy.
描述(由适用提供):高血糖是发展糖尿病微血管并发症的主要危险因素。 ADA建议将T2DM个体中的A1C降低到水平(即HBA1C <6.0-6.5%)“在避免低血糖症的同时,尽可能接近正常”。实现此目标的最佳药理疗法尚未确定。 We have demonstrated that starting newly diagnosed T2DM Individuals on a combination of agents (metformin, pioglitazone, exenatide) which correct known pathophysiological defects in T2DM (Triple Therapy) produces a greater decrease in HbA1c compared to stepwise addition of metformin, sulfonylurea and insulin (Conventional Therapy) and that the decrease in HbA1c was maintained for 36 months of后续。与接受三重治疗的受试者相比,接受常规疗法的受试者的体重增加(3.7 kg)和降血糖事件的率高(7.4倍)。此外,与常规疗法相比,三重治疗可导致胰岛素敏感性和β细胞功能的大幅提高。在这笔赠款中,我们建议继续遵循目前活跃的受试者36个月,以获取有关与常规治疗相比,三重治疗的长期效率,耐用性,安全性和作用机理的信息。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.
- DOI:10.2337/dc16-1738
- 发表时间:2017-03
- 期刊:
- 影响因子:16.2
- 作者:Abdul-Ghani M;Migahid O;Megahed A;Adams J;Triplitt C;DeFronzo RA;Zirie M;Jayyousi A
- 通讯作者:Jayyousi A
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RALPH A DEFRONZO其他文献
RALPH A DEFRONZO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RALPH A DEFRONZO', 18)}}的其他基金
Targeting hepatic mitochondrial function in humans with NAFLD using insulin sensitizers
使用胰岛素增敏剂靶向 NAFLD 患者的肝线粒体功能
- 批准号:
10601098 - 财政年份:2022
- 资助金额:
$ 48.88万 - 项目类别:
Targeting hepatic mitochondrial function in humans with NAFLD using insulin sensitizers
使用胰岛素增敏剂靶向 NAFLD 患者的肝线粒体功能
- 批准号:
10446388 - 财政年份:2022
- 资助金额:
$ 48.88万 - 项目类别:
Ketones, Muscle Metabolism, and SGLT2 Inhibitors
酮、肌肉代谢和 SGLT2 抑制剂
- 批准号:
10595032 - 财政年份:2016
- 资助金额:
$ 48.88万 - 项目类别:
SGLT2 INHIBITION AND STIMULATIION OF ENDOGENOUS GLUCOSE PRODUCTION
SGLT2 抑制和刺激内源性葡萄糖产生
- 批准号:
9032300 - 财政年份:2016
- 资助金额:
$ 48.88万 - 项目类别:
Ketones, Muscle Metabolism, and SGLT2 Inhibitors
酮、肌肉代谢和 SGLT2 抑制剂
- 批准号:
10713358 - 财政年份:2016
- 资助金额:
$ 48.88万 - 项目类别:
Ketones, Muscle Metabolism, and SGLT2 Inhibitors
酮、肌肉代谢和 SGLT2 抑制剂
- 批准号:
10632818 - 财政年份:2016
- 资助金额:
$ 48.88万 - 项目类别:
Ketones, Muscle Metabolism, and SGLT2 Inhibitors
酮、肌肉代谢和 SGLT2 抑制剂
- 批准号:
10445180 - 财政年份:2016
- 资助金额:
$ 48.88万 - 项目类别:
Durability of Early Combination Therapy vs Conventional Therapy in New Onset T2DM
早期联合治疗与传统治疗在新发 T2DM 中的持久性
- 批准号:
9130823 - 财政年份:2015
- 资助金额:
$ 48.88万 - 项目类别:
Durability of Early Combination Therapy vs Conventional Therapy in New Onset T2DM
早期联合治疗与传统治疗在新发 T2DM 中的持久性
- 批准号:
8965261 - 财政年份:2015
- 资助金额:
$ 48.88万 - 项目类别:
Regulation of Hepatic and Peripheral Glucose Metabolism
肝脏和外周葡萄糖代谢的调节
- 批准号:
8000968 - 财政年份:2009
- 资助金额:
$ 48.88万 - 项目类别:
相似海外基金
Detection of Emergent Mechanical Properties of Biologically Complex Cellular States
生物复杂细胞状态的紧急机械特性的检测
- 批准号:
10832871 - 财政年份:2023
- 资助金额:
$ 48.88万 - 项目类别:
Exercise Mimetics for Dementia and Alzheimer's Disease
治疗痴呆和阿尔茨海默病的模拟运动
- 批准号:
10586188 - 财政年份:2023
- 资助金额:
$ 48.88万 - 项目类别:
Metabolic Reprogramming by Protease-activated Receptor 2
蛋白酶激活受体 2 的代谢重编程
- 批准号:
10365793 - 财政年份:2022
- 资助金额:
$ 48.88万 - 项目类别:
Metabolic Reprogramming by Protease-activated Receptor 2
蛋白酶激活受体 2 的代谢重编程
- 批准号:
10569593 - 财政年份:2022
- 资助金额:
$ 48.88万 - 项目类别:
Hyaluronan as a mediator of intrauterine growth restriction-induced islet dysfunction in type 2 diabetes
透明质酸作为 2 型糖尿病宫内生长受限诱导的胰岛功能障碍的介质
- 批准号:
10303293 - 财政年份:2021
- 资助金额:
$ 48.88万 - 项目类别: